JW AND JZ MODIFIER

For 2025, the Centers for Medicare & Medicaid Services (CMS) requires the use of both the JW and JZ modifiers for separately payable drugs from single-dose containers to ensure accurate tracking of drug wastage and support the Discarded Drug Refund Program, CMS will return or deny claims for applicable drugs submitted without these modifiers. Therefore, understanding how JW and JZ modifiers work is crucial for compliance

According to the CMS single-dose vial policy, accurate use of these coding modifiers—the modifier jw and modifier jz—is essential for compliance under Medicare Part B drug billing regulations.

Understanding what is jz modifier and how it differs from the modifier jw helps healthcare providers ensure accurate claim submissions.

The JW JZ modifier reference guide from CMS outlines all compliance updates for 2025. Proper usage supports Medicare drug billing support systems and aligns with JW JZ modifier coding tips for precise claim processing.

JZ Modifier: Zero Drug Amount Discarded 

The JZ modifier description stares that no amount of the drug from a single-dose container was discarded. This means the entire usable contents of the single-use vial or package were administered to the patient

JZ Modifier Updates and For Example (2025)

• The Modifier JZ is mandatory for all claims where no drug amount from a single-dose container is discarded, ensuring compliance with the CMS single-dose vial policy.
• As of January 1, 2024, the modifier JZ is also required for drugs dispensed by a supplier for patient self-administration at home
• if no amount was discarded during preparation. Example: For a 100 mg single-dose vial (HCPCS JXXXX, 10 mg = 1 unit) where the full 100 mg is administered, the billing would be JXXXX, 10 units, with the modifier JZ. Documentation must confirm the full amount was administered with no discard as per the JW JZ modifier coding tips.

JW Modifier: Drug Amount Discarded

The JW modifier description explains the amount of a separately payable drug from a single-dose container that was discarded and not administered. The modifier jw is widely used in compliance with the CMS single-dose vial policy and follows Medicare Part B drug billing guidelines.

JW Modifier Updates and Example (2025)

• Report the JW modifier on a separate claim line for the discarded amount, as stated in the JW JZ modifier reference guide.
• Effective January 1, 2025, the modifier JW is also required for suppliers who discard amounts during preparation
• Before providing the drug to the patient, ensuring accurate reporting between jz vs jw modifier categories.
• Example: If an 80 mg dose is needed from a 100 mg single-dose vial (HCPCS JXXXX, 10 mg = 1 unit) and 20 mg is discarded, the billing would be Line 1: JXXXX, 8 units (administered) and Line 2: JXXXX, 2 units (discarded) with the modifier JW. Documentation needs to detail the vial size, administered amount, discarded amount, and reason for discard in line with Medicare drug billing support and JW JZ modifier coding tips.

Key General Guidelines for JW JZ modifier coding 

• These modifiers apply only to separately payable drugs from single-dose containers under Medicare Part B drug billing. They do not apply to multi-dose vials or packaged drugs as per the CMS single-dose vial policy and JW JZ modifier reference guide.
• If the administered dose is less than the HCPCS billing unit, bill one unit with the  modifier JZ; the modifier JW modifier is not used, ensuring correct distinction between jz vs jw modifier usage.
• Coders must thoroughly document vial size, administered amount, discarded amount, and reason for discard.

• Based on Medicare billing guidelines, the following are common examples of drugs (identified by HCPCS codes) from single-dose containers that require either the JW or JZ modifier or jz and jw modifier in accordance with Medicare drug billing support.
• The specific list of drugs is extensive and regularly updated, but these are frequently cited categories and examples under JW JZ modifier coding tips.

Oncology and chemotherapy drugs 

• Ado-trastuzumab: Used in certain cancer treatments under Medicare Part B drug billing and may require the jw and jz modifier.
• Bevacizumab (Avastin): Used for various cancers following the CMS single-dose vial policy and JW JZ modifier reference guide.

• HCPCS code: J9035 (10 mg)
• HCPCS code: C9257 (Bevacizumab injection)

• Doxorubicin liposomal: An oncology agent requiring proper coding modifiers like modifier jw or modifier jz depending on discard.
• Durvalumab: An immunotherapy agent billed with Medicare drug billing support.
• Fluorouracil: Can be used in cancer treatment with JW JZ modifier coding tips.

• HCPCS code: J9190 (500 mg)

• Irinotecan (Camptosar): A chemotherapy drug applicable under jz and jw modifier
• Nivolumab: An immunotherapy agent subject to JW JZ modifier reference guide
• Pembrolizumab: An immunotherapy agent requiring proper jw modifier in medical billing for discarded portions.
  • HCPCS code: J9271
• Trastuzumab (Herceptin): Used for certain cancers as per Medicare Part B drug billing.
  • HCPCS code: J9355 (10 mg) 

Immunology and inflammatory drugs

• Abatacept: A drug for rheumatoid arthritis billed using correct coding modifiers such as modifier jw or modifier jz under the CMS single-dose vial policy.
• Adalimumab: A drug for various autoimmune conditions requiring accuracy in jw modifier in medical billing and compliance with JW JZ modifier coding tips.
• HCPCS code: J0139 (1 mg)
• HCPCS code: J0135 (20 mg)

• Eculizumab: Used for specific rare blood disorders and billed under Medicare Part B drug billing using jz vs jw modifier based on wastage.
• Infliximab (Remicade): An anti-inflammatory drug documented with jw and jz modifier as per Medicare drug billing support.
• HCPCS code: J1745 (10 mg) 

Ophthalmology drugs

• Aflibercept (Eylea): A drug used for wet macular degeneration and other retinal conditions; ensure proper billing using modifier jw and modifier jz under CMS single-dose vial policy.

• Bevacizumab (Avastin): Used off-label for ophthalmology; follow jw modifier description and jz modifier description when reporting discarded or fully used doses under Medicare Part B drug billing.
• Ranibizumab (Lucentis): Used for age-related macular degeneration; refer to JW JZ modifier reference guide for applying jz and jw modifier in claims submission.
• Vabysmo: A drug used for wet macular degeneration; coding accuracy depends on whether jz vs jw modifier applies, as outlined in JW JZ modifier coding tips.
• Cimerli: A biosimilar drug used for wet macular degeneration; ensure Medicare drug billing support compliance by including correct coding modifiers for wastage reporting.

Neuromuscular drugs

• OnabotulinumtoxinA (Botox): Used for various neuromuscular conditions; ensure accurate reporting with modifier jw or modifier jz as per CMS single-dose vial policy.

• HCPCS code: J0585 — apply JW JZ modifier coding tips when billing under Medicare Part B drug billing for wastage or full usage documentation.

Other injectable and biological drugs

• Amifostine: Used to protect against certain side effects of chemotherapy; follow jw modifier description for wastage reporting.
  • Darbepoetin alfa: A drug used to treat anemia; include jz modifier description when no wastage occurs, ensuring Medicare drug billing support.
  • Epoetin alfa: Used to treat anemia associated with chronic kidney disease; verify claim accuracy with jz and jw modifier under JW JZ modifier reference guide.
  • Pegfilgrastim (Neulasta): Used to treat low white blood cell counts; ensure compliance with jz vs jw modifier rules and coding modifiers documentation.
  • HCPCS code: J2505 (6 mg) — billed according to JW JZ modifier coding tips and CMS single-dose vial policy.

To Summarize How to identify applicable drugs

These modifiers are required for any Medicare Part B drug billing that involves a separately payable drug supplied in a single-dose container. Therefore, to determine if a specific drug needs a JW JZ modifier, look for these indicators:

• FDA Labelling: Check if the drug is labelled for single-dose use and refer to JW JZ modifier reference guide for compliance.
• CMS and MAC Policy: Review documentation from the Centers for Medicare & Medicaid Services (CMS) and your local Medicare Administrative Contractor (MAC) — this aligns with Medicare drug billing support.
• HCPCS Code Descriptors: Many HCPCS code descriptors specify a billing unit smaller than the vial size, requiring jw and jz modifier as per JW JZ modifier coding tips.